Investor Overview

Corporate Profile
REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. The Company’s NAV Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. The Company’s mission is to transform the lives of patients suffering from severe diseases with significant unmet medical needs by developing and commercializing in vivo gene therapy products based on the Company’s NAV Technology Platform. The Company seeks to accomplish this mission through a combination of internal development efforts and the efforts of the Company’s third-party licensees.
RGNX (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$31.10
Change (%) Stock is Down 1.65 (5.04%)
Volume376,899
Data as of 10/23/17 4:00 p.m. ET
Refresh quote
Data provided by Nasdaq. Minimum 15 minutes delayed.
Stock chart for: RGNX.O.  Currently trading at $31.10 with a 52 week high of $36.10 and a 52 week low of $15.40.
Recent NewsMore >>
DateTitle 
10/03/17REGENXBIO to Present at Upcoming Investor Conferences
ROCKVILLE, Md., Oct. 03, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will present at the following October investor conferences: Chardan Inaugural Gene Therapy Conference Date: Tuesday, October 10, 2017 Location: The Westin New York Grand Central Hotel Fireside chat: Tuesday, October 10... 
Printer Friendly Version
10/02/17REGENXBIO Responds to Notification of a Superior Proposal Under Its Merger Agreement With Dimension Therapeutics
Company Focused on Advancing Proprietary NAV Technology Platform and Deep Gene Therapy Treatment Pipeline ROCKVILLE, Md., Oct. 02, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX) today announced that Dimension Therapeutics, Inc. (Nasdaq:DMTX) notified REGENXBIO that it has determined that it has received a “superior proposal” as defined in the merger agreement under which REGENXBIO would have acquired Dimension in an all-stock transaction for an implied value of approximately $3.41 per ... 
Printer Friendly Version
09/20/17REGENXBIO Announces Completion of Dosing of First Cohort in Phase I Clinical Trial of RGX-314 Gene Therapy for Wet AMD
Six patients dosed at leading retinal surgery centers in the United States All participating study centers now active; next dose cohort is projected to start after review by the Data Safety Monitoring Board this month Clinical trial evaluates one-time treatment for wet AMD using NAV® AAV8 gene therapy; interim trial update expected by year-end 2017              ROCKVILLE, Md., Sept. 20, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology comp... 
Printer Friendly Version
08/31/17REGENXBIO to Present at Upcoming Investor Conferences
ROCKVILLE, Md., Aug. 31, 2017 (GLOBE NEWSWIRE) --  REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will present at the following September investor conferences: Citi 12th Annual Biotech Conference Dates: Wednesday, September 6 – Thursday, September 7 Location: Mandarin Oriental, Boston Panel: Gene Therapy Manufactu... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Presentations
DateTitle
10/03/17
Corporate PresentationDownload Documentation 
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever REGENXBIO posts new information to the site. Just enter your e-mail address and click Submit.